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ABSTRACT Ankylosing spondylitis (AS) belongs to a group of autoimmune diseases affecting the axial skeleton. Beside 
the hla-b*27 allele, several other human genes that control the variety processes of immune homeostasis are considered 
to be associated with AS manifestation in different human populations.  Among strong associated non-MHC genes 
erap1 encoding the endoplasmic reticulum aminopeptidase 1 isoform was recently identified by single nucleotide poly-
morphisms (SNPs) meta analysis. In our study we inspected the genetic association of five non-synonymous coding 
SNPs from erap1 with AS in Caucasians. We implemented the SSP-PCR system for precise genotyping of 87 hla-b*27 
positive AS patients and 77 hla-b*27 healthy donors from the Russian population. Considerable differences in allele’s 
frequencies within patients vs control cohort were shown for 3 of 5 SNPs under investigation. Using the EM-algorhitm 
we reconstructed 3-marker haplotypes that distinguish with high probability two cohorts due to differences in the 
haplotypes frequencies. In such a way both the sensitive, CCT, haplotype and the protective, TTC, one were predicted.   
To verify the calculation we determined genuine frequencies of  5-marker haplotypes in AS cohort by haplotyping of 
individual cDNA samples using improved SSP-PCR primer set. We demonstrated that the frequencies of in silica re-
constucted haplotypes and the frequencies of experimentally detected haplotypes are in a good agreement. Frequency 
of the risk haplotype CCT (rs17482078/10050860/2287987) detected within AS cohort reaches 88%, as well as the 
frequency calculated by EM-algorhitm.
KEYWORDS  aminopeptidase ERAP1, human single nucleotide polymorphism, allele-specific PCR, human haplotypes, 
ankylosing spondylitis.
ABBREVIATIONS  AS -  ankylosing spondylitis, ER - endoplasmic reticulum, MHC - major histocompability complex, 
TNF - tumor necrosis factor, TNFR - tumor necrosis factor receptor, IL - interleukin. 
INTRODUCTION
Ankylosing spondylitis (AS) is one of autoimmune dis-
eases belonging to spondyloarthropathy. The disease 
is characterized by an inflammation of axial skeleton 
joints and a resulting formation of ossified regions in 
the joints. The first symptoms of the disease appear 
at the age of 20-25, and then it slowly progresses. Re-
cently several genetic loci have been found to be as-
sociated with the desease. The products of these genes 
are involved in various stages of the immune response. 
According to results of twins studies the concordance 
in monozygote twins varies from 26 to 60%, whereas for 
dizygote twins the concordance varies from 4 to 20%. 
This evidence underlies the importance of the genetic 
background for AS development [1-3]. 
The strongest association was observed for the hla 
B*27 allelic variant of the MHC-I gene. Approximately 
90% of patients of European descent suffering from AS 
bear this allele; however, only 5% of Europeans car-
rying the allele are affected by the desease [4]. Large-
scale full-genome comparisons of diagnosed patients 
cohorts with healthy people show that several other 
SNPs in non-MHC-I genomic loci are also associated 
with the disease. These loci have a weaker association 
with the risk of developing AS. Among the non-MHC 
loci, the strongest association was observed for the 
erap1 aminopeptidase gene [5, 6]. 
ERAP1 aminopeptidase acts in a variety of immune 
response stages. The difference of ERAP1 functioning 
probably exists due to its different intracellular locali-
zations. ERAP1 is mainly located in the endoplasmic re-
ticulum (ER) in human and murine cells. However, the 
protein also might be expressed on the outer surface 
of the cytoplasmic membrane or be secreted into the 
extracellular environment [7]. One of the functions of 
ERAP1 is the N-terminal proteolysis of peptides, which 
are formed during the proteasome-dependent degrada-
tion of cellular proteins. The formed peptides are then 
exposed on the cell’s surface by MHC-I molecules. Also 
ERAP1 might be involved in the formation of the solu-
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ble form of the type I tumor necrosis factor receptor 
(TNFR-1), along with the soluble forms of interleukin 
1 and 6 (IL) receptors. ERAP1 thus plays an important 
role in the regulation of the immune response [8-10]. 
Studies of cohorts of different ethnicities and vary-
ing genetic homogeneities in terms of the hla-b allele 
content reveled in identification of several non-syn-
onymous SNPs in the coding region of the erap1 gene 
which are associated with an increased risk of AS [11-
15]. The sets of AS-associated polymorphisms detected 
in these studies are different. It is probably due to the 
genetic properties of the cohorts under investigation. 
The presence of amino acid substitutions and/or 
their combinations in ERAP1 variants may result in 
changes in the aminopeptidase activity. These substi-
tutions may also result in the deregulation of peptide 
processing and control over immune cells via TNF or 
IL-1 and -6. The putative ability of ERAP1 variants 
bearing substitutions to form inappropriate peptides 
on MHC-I is considered as the aminopeptidase impact 
on AS progression. The hypothesis assumes a misrec-
ognition of the presented peptides as alien signals, and 
it leads, in turn, to an increase of empty MHC-I or its 
dimmers consisting exclusively of heavy chains on cell’s 
surface. Finaly these processes could result in the for-
mation of nonspecific immune responses against cells 
that expose the misfolded MHC-I [16]. Dysfunction of 
ERAP1 activity aimed at IL receptors could be another 
explanation of the mutant aminopeptidase involvment 
in AS progression. 
In our research, we have determined the frequencies 
of erap1 allele variants and corresponding genotypes 
for 5 non-synonymous SNPs  in cohorts of AS patients 
and healthy individuals from the Russian population. 
Both the AS patients cohort and healthy group consist 
of hla-B*27 positive individuals. Markers rs2287987 
(Met349Val), rs30187 (Lys528Arg), rs10050860 (As-
p575Asn), rs17482078 (Arg725Gln), and rs27044 
(Glu730Gln) were selected for the genotyping. Each of 
the markers have been previously associated with AS 
by other authors [11-15]. The location of these non-syn-
onymous substitutions within the coding region of the 
erap1 gene allows us to imply the existence of functional 
effects of the corresponding amino acid substitutions. 
We used the genotyping results for haplotypes re-
construction and for association analysis of the  erap1 
allele variants with AS.
MATERIALS AND METHODS
Genomic DNA and RNA samples
The samples of genomic DNA were purified from the 
peripheral blood of 77 hla-B*27 positive healthy donors 
aged 21-63, and of 84 hla-B*27 positive patients with 
the axial form of AS. Genomic DNAs were extracted 
from the peripheral blood mononuclear cells using a 
Diatom Prep 100 kit (Izogen Laboratory, Moscow) ac-
cording to the manufacturer’s protocol. 
Samples of total RNA were extracted from periph-
eral blood mononuclear cells using TRIzol® Reagent 
(Invitrogen Lifetechnologies, USA), according to the 
manufacturer’s protocol. 
cDNA synthesis
1-2 micrograms of total RNA were used for cDNA syn-
thesis. The first strands of cDNAs were synthesized us-
ing the “Mint-Universal cDNA synthesis kit” (Eurogen, 
Russia) according to the manufacturer’s protocol. 
Geno- and haplotyping
Genotyping was performed using a set of allele-specific 
PCR primers (Table 1). Each pair consisted of an allele-
specific primer complementary to the allele variant and 
a primer specific to the nearest intron. The presence of 
the distinct allele in a sample was determined by the 
presence/absence of the specific PCR products. Allele-
specific PCR on cDNA templates using subsets of four 
allele-specific primers corresponding to each pairs of 
SNPs was performed for haplotyping. 
To enhance the allele discrimination ability a mismatch 
was introduced in the third position of the primer 3’-end 
of each of the allele-specific primers. Geno- and haplo-
typing results have been independently reproduced at 
least twice for each sample. Additionally concordance of 
the geno- and haplotyping results was inspected.
“HS Taq-DNA-polymerase kit” (Eurogen, Russia) was 
used for PCR amplification; the final volume of the reac-
tion mixture was 15 microliters; the annealing tempera-
Table 1. Sequence of the primers used in this study
Primer Sequence of nucleotides (5’–3’)
30-A For ATGAACACTTGGACACTGCACAA
30-G For ATGAACACTTGGACACTGCACAG
27-C Rev CACACAGGCGAGGAGTAGTAGATC
27-G Rev CACACAGGCGAGGAGTAGTAGATG
100-G For CATTCATCACCAGCAAATGCG
100-A For CATTCATCACCAGCAAATGCA
174-T Rev TAGTAGTTSACTCCGCAGCAATT
174-C Rev TAGTAGTTSACTCCGCAGCAATC
228-A For ATCAAGTAAGCTTGGCATCAGAA
228-G For ATCAAGTAAGCTTGGCATCAGAG
228 int AACAAATTAACCTCAAATGTGAAG
30 int CCTCCTTAATCCTACTGGGAAGAT
100 int GGCCATACATATGATATAACCCAGTA
174&27 int CTGGGACTCTTCATGGTACTTGAG74 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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ture was set at 65°C; 30 and 33 cycles of PCR were im-
plemented to amplify DNAs and cDNAs, respectively. 
Statistical analysis
Haploview 4.1 (http://www.broadinstitute.org/
haploview/haploview) and Genetic Data Analysis 
(Lewis, P. O., and Zaykin, D. 2001. Genetic Data Analy-
sis: Computer program for the analysis of allelic data. 
http://lewis.eeb.uconn.edu/lewishome/software.html) 
software was used to analyze the results of geno- and 
haplotyping.
Hardy-Weinberg equilibriums for erap1 alleles were 
tested using Fischer exact test, as well as the exact test 
described by G. Abecasis and J. Wigginton [17].
The statistical significance of the differences in the 
allele frequencies were analyzed using the χ2 test with 
Yate’s correction. The value of the risk factor (OR) and 
the confidence interval (CI 95%) were calculated using 
an online calculator: www.openepi.com. 
Expectation-maximization algorithm (EM-algorithm) 
of  Haploview 4.1 software was used to detect linkage 
disequilibrium (LD) of tested SNPs and to calculate the 
frequencies of reconstructed haplotypes. Strong LD 
was defined as D’ ≥ 0.8 CI95% 0.7–0.99 [18].
Bayesian algorithm of PHASE 2.1 software was im-
plemented to confirm the frequencies of reconstructed 
haplotypes.
RESULTS AND DISCUSSION
The frequencies of minor allelic variants of the erap1 
gene are decreased in AS patients
By using a set of allele-specific primers (Table 1, Fig. 
1), we identified the frequencies of 10 allelic variants 
of the erap1 gene and the corresponding genotypes 
in hla-B27 positive cohorts of 84 AS patients and 77 
healthy donors. The allelic variants of the erap1 gene 
were distinguished by the set of non-synonimous SNPs: 
rs2287987 (C/T, Met349Val), rs30187 (C/T, Lys528Arg), 
rs10050860 (C/T, Asp575Asn), rs17482078 (C/T, Ar-
g725Gln), and rs27044 (C/G, Glu730Gln). These pol-
ymorphysms code the amino acid substitutions in 
ERAP1. The protein variants bearing the substitutions 
might be functionally different and therefore play a 
positive or protective role in AS progression. Associa-
tion of each of 5 markers with ankylosing spondylitis 
was published recently by several authors [11-15]. Two 
of the five SNPs are “located” near the putative active 
sites of the aminopeptidase; rs2287987 – is located near 
the Zn2+ ion-binding site [11], while rs30187 is located 
near the putative substrate-binding pocket. 
Distribution of 5 allele pairs in both the AS patients 
and the control cohorts showed no significant devia-
tions from the Hardy-Weinberg Equilibrium. 
Analysis of the genotyping results showed that the 
frequencies of three minor alleles of rs2287987 (p< 
0.002, OR = 0.35), rs10050860 (p < 0.004, OR = 0.39), and 
rs17482078 (p < 0.05, OR = 0.52) markers are signifi-
cantly lower among AS patients compared to healthy 
donors in the Russian population (Table 2). An asso-
ciative analysis test shows that three allelic variants 
228 For A  30 For A   100 For A   174&27 int
228 int   30 int  100 int 
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Fig. 1. Scheme of sequence-specific primer positions for erap1 allele detection Introns and exons of erap1 and size of 
PCR-products are shown.
D575N
K528L
M349V
Q730E R725Q
Figure 2. Ribbon model of putative human ERAP1 struc-
ture (modified from [11]). Amino acid substitutions 
encoded by SNPs studied in this work are highlighted. 
Corresponding amino acid residues are marked by blue 
balls. The putative active site of ERAP1 is denoted by 
cyan circle with a red sphere representing a Zn atom.RESEARCH ARTICLES
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of erap1 are associated with an increased risk of AS 
(rs2287987 [T] (OR = 2.86), rs10050860 [C] (OR = 2.54), 
and rs17482078 [C] (OR = 1.91). However, our results 
also show a lack of a significant association of rs30187 
and rs27044 polymorphisms with AS in the Russian 
population. 
Decreased frequencies of minor alleles of rs2287987, 
rs10050860, and rs17482078 markers are accompanied 
by a decreased number of heterozygous individuals and 
an increased number of homozygous for the major al-
lele individuals in the AS patient group as compared to 
the control group. Heterozygocity for the rs30187 and 
rs27044 markers, which are not associated with AS in 
the Russian population, increases in AS patients, al-
though the minor allele frequencies do not differ sig-
nificantly AS patients from healthy individuals. 
In general our data are in a good agreement with 
those reported by other researchers. Several studies 
have shown that all five of the inspected markers are 
associated with the risk of AS [5, 6, 11], although the co-
horts of AS patients and healthy individuals included a 
considerable number of hla-B27-negative donors. Two 
other studies [14, 15] were performed on cohorts consist-
ing of  hla-B27-positive donors exclusively or mostly (77-
85%). No association with AS was found for the rs30187 
and rs17482078 markers, while rs2287987, rs10050860, 
and rs27044 proved to be associated with the AS risk 
[14]. In another study [15] it was demonstrated that al-
lelic variants for the markers rs10050860 and rs30187, 
but not rs27044, were associated with the AS risk.
Statistically significant association of rs27044 
and rs30187 but not of rs2287987, rs10050860, and 
rs17482078 markers with AS was reported for the Ko-
rean population [12].
The differences between the results of the associa-
tive analyses are most likely due to considerable differ-
ences between the studied populations in erap1 allele 
frequencies. Another reason for the incongruence be-
tween the cited results might be the different presenta-
tion of hla-B27 positive individuals in the cohorts under 
comparison. In our study, special attention was focused 
on the genetic homogeneity of the cohorts in terms of 
the hla-b27 carriership and on the uniformity of clini-
cal manifestations of the disease. Such considerations 
helped us avoid risk of false positive associations. 
Haplotype reconstruction based on obtained genotype 
data
The genotyping results for both cohorts were used 
to calculate haplotype frequencies. We searched for 
haplotypes whose frequencies increased statistically 
significantly in AS patients and could, thus, be associ-
ated with AS risk. We used Haploview 4.1 software to 
identify the linkage disequilibrium between the pairs 
of the studied markers. Polymorphisms rs2287987, 
rs10050860, and rs17482078 proved to be in statistically 
Table 2. Frequencies of allelic variants and genotypes for the studied genetic markers in two cohorts
Marker, 
polymorphic 
nucleotide
AS patients, n = 84 Healthy donors, n = 77 
p OR
(95%CI)
MAF*
[nucleotide in minor 
allele]
Number of 
genotypes 
(frequency)
MAF*
[nucleotide in minor 
allele]
Number  
of genotypes 
(frequency)
rs2287987 [C/T] 0.09
[C]
СС 1 (0.01)
0.22
[C]
СС 3 (0.04)
0.002 0.35
(0.18–0.68) CT 13 (0.15) CT 26 (0.36)
TT 70 (0.84) TT 44 (0.60)
rs30187 [C/T] 0.37
[T]
СС 29 (0.35)
0.33
[T]
СС 35 (0.45)
0.55 1.18
(0.75–1.87) CT 48 (0.57) CT 33 (0.43)
TT 7 (0.08) TT 9 (0.12)
rs10050860 
[C/T]
0.11
[T]
СС 66 (0.78)
0.23
[T]
СС 46 (0.60)
0.004 0.39
(0.21–0.73) CT 18 (0.21) CT 26 (0.34)
TT - TT 5 (0.06)
rs17482078 
[C/T]
0.13
[T]
СС 65 (0.77)
0.21
[T]
СС 47 (0.61)
0.046 0.52
(0.29–0.95) CT 17 (0.20) CT 27 (0.35)
TT 2 (0.02) TT 3 (0.04)
rs27044 [C/G] 0.33
[G]
GG 7 (0.08)
0.29
[G]
GG 9 (0.12)
0.47 1.23
(0.76–1.97) GC 42 (0.5) GC 26 (0.34)
CC 35 (0.42) CC 42 (0.55)
*MAF – minor allele frequency76 | ACTA NATURAE |  VOL. 2  № 3 (6)  2010
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significant pairwise linkage disequilibrium (D’ ≥ 0.85, 
95%CI 0.76–0.99, according to [18]) and were grouped 
into a single block. The theoretical haplotype frequen-
cies in both AS patients and healthy cohorts were cal-
culated for markers belonging to this block. Haplotypes 
with theoretical frequencies below 5% were discounted 
from further analysis.
The CCT haplotype was found to be statistically sig-
nificantly associated with AS risk (p < 0.03, OR = 1.96). 
The calculated frequency of the TTC haplotype was 
to be lower in AS patients as compared to the healthy 
individuals (p <0.003, OR = 0.33) (Table 3). 
Haplotyping of AS patients in Russian population 
Using paired combinations of allele-specific primers 
and cDNA samples we identified erap1 gene haplotypes 
in the same cohort of AS patients. Table 4 lists the fre-
quencies of the identified 5-marker haplotypes in the 
patients cohort. Haplotypes consisting of only 3 mark-
ers associated with AS in the Russian population were 
listed specifically. The table does not list haplotypes 
with frequencies of less than 5%, with the exception of 
TTC haplotype, which was determined as a putative 
protective haplotype based on theoretical calculations.
The determined frequency of the putative risk hap-
lotype CCT among AS patients was approximately 
88%. The percentage is in agreement with the calcu-
lated frequency value. The frequency of the putative 
protective TTC haplotype is approximately 1%, while 
the calculated value is approximately 8% (Table 3). This 
difference could be attributed to the insufficient size of 
the AS patients cohort for a statistically representative 
identification of the actual frequency of the protective 
haplotype. 
The identified risk haplotype includes mostly those 
SNP variants that were demonstrated to be risk-asso-
ciated in other cohorts of Eropeans (Table 5). 
Notably recent researchs has yielded controversial 
data regarding the risk-associated haplotypes for the 
markers rs27044 and rs30187 in different populations. 
Maksymowych et al. [14] reported a risk association for 
the C-allele (marker rs27044), while a study by Pazar 
et al. [15] showed that both identified risk haplotypes 
include G-allele of the same marker. Moreover, the two 
risk haplotypes identified in the cited study [15] are in-
variant for the rs30187 marker. These results, as well as 
the controversial data on the association of erap1 gene 
allele variants for markers rs27044 and rs30187 with 
AS risk, may indicate that the amino acid substitutions 
encoded by these polymorphisms do not affect the ac-
tivity of the aminopeptidase, nor its role in AS. The de-
scribed associations may be due to the heterogeneity 
of the patient cohorts or/and genetic linkage of these 
polymorphisms with other non-synonymous substitu-
tions which result in changes of aminopeptidase func-
tion that is essential for AS. 
The published results of the few in vitro studies in-
dicate that a Lys528Arg substitution, encoded by the 
SNP rs30187, has a strong effect on ERAP1 aminopepti-
dase activity. Goto et al. [19] demonstrated that the 
ERAP1 variant, which has Arg in position 528, displays 
low peptidase activity to synthetic substrates as well to 
the natural substrates (angiotensin II and kallidin). In 
the cited study [19] it was also shown that substitution 
Gln730Glu, encoded by the polymorphism rs27044, and 
substitution Asp575Asn, encoded by the polymorphism 
rs10050860, have almost no effect on peptidase activ-
ity to synthetic and natural substrates. Transient ex-
Table 3. Calculated frequencies of reconstructed haplotypes including markers rs17482078/10050860/2287987, as-
sociated with risk of AS in Russian population. 
Haplotype Frequency in AS patients,  
n = 84
Frequency in healthy donors, 
 n = 77 р OR
(95%CI)
ССТ 0.86 0.75 0.026 1.96
(1.12–3.46)
ТТС 0.08 0.2 0.003 0.33
(0.17–0.67)
Table 4. Distribution of identified haplotypes in a AS pa-
tient cohort of the Russian population
Haplotype* Number of haplotypes in AS patient  
(frequency), n = 69
rs27044/17482078/10050860/30187/2287987
CCCCT 70 (0.51)
GCCTT 36 (0.26)
GCCCT 8 (0.06)
CCCTT 7 (0.05)
GTTGT 7 (0.05)
СТТСС 2 (0.01)
rs17482078/10050860/2287987
ССТ 121 (0.88)
TTT 7 (0.05)
ТТС 2 (0.01)
*Nucleotides which are a part of the predicted protective 
and risk –associated haplotypes are underlined and bold.RESEARCH ARTICLES
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pression of erap1 in a melanoma cell line demonstrated 
that the amino acid substitution Met349Val (polymor-
phism rs2287987) increased ERAP1 peptidase activ-
ity to a synthetic substrate [20]. Comparison of amino 
acid substitutions characterized in the previously cited 
articles with our associative analysis data, and other 
similar findings by other authors (Table 5), suggests 
that some of the AS-associated non-synonymous sub-
stitutions can alter ERAP1 peptidase activity. However, 
most of the desease-associated alleles are likely to have 
other functional manifestations, since the correspond-
ing amino acid substitutions do not affect the enzyme’s 
activity on synthetic substrates. 
Seemingly disagreement between the results of 
functional tests and the associative analysis can be 
overcomed by identification of haplotypes specific for 
healthy cohorts of patients. In our study, we have iden-
tified risk-associated CCT and protective TTC haplo-
types for the markers rs17482078/10050860/2287987. 
The frequency of both haplotypes is statistically signif-
icantly increased in the corresponding cohort (Table 4). 
One of the substitutions encoded by the protective hap-
lotype (Met349Val) increases ERAP1 activity on sev-
Table 5. Allelic variants of erap1, associated with increased risk of AS development in various populations
rs27044 rs17482078 rs10050860 rs30187 rs2287987 reference
С - С T - [14]
G C C T T [15]
G C C C T [15]
G C C T - [12]
G  - - T - [13]
- C C - T this study
eral substrates [20]. This fact suggests that increased 
ERAP1 activity might prevent AS. The protective ef-
fect of the TTC haplotype may be due to the activity 
of ERAP1 towards receptors of proinflammatory cy-
tokines or due to the correct presentation of peptides 
on MHC-I molecules. In contrast, the non-synonymous 
substitutions included in the risk haplotype CCT could 
lead to increased levels of membrane-bound forms of 
TNFR-1 and receptors for IL-6 and -1. 
Considering that AS is a multigene disease, further 
research for the ERAP1 role in AS should be focused on 
both identification of the function features of different 
erap1 allele variants and study of the putative interac-
tions between the enzyme and the products of other 
genes associated with the disease. These interactions 
may indeed be affected by the non-synonymous sub-
stitutions in the risk haplotype of the erap1 gene which 
we have identified in the Russian population. 
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